Galmed Pharmaceuticals (GLMD) EPS (Basic) Growth (1y) (2014 - 2025)
Galmed Pharmaceuticals (GLMD) EPS (Basic) Growth (1y) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | -16.29% |
| 10 | Galmed Pharmaceuticals | 2.34 Mn | -9.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -94.93% |
| Jun 30, 2024 | -53.64% |
| Jun 30, 2023 | -100.00% |
| Sep 30, 2022 | -157.92% |
| Sep 30, 2021 | -99.96% |
| Mar 31, 2021 | -50.77% |
| Dec 31, 2020 | -585.40% |
| Sep 30, 2020 | 3,703,383.57% |
| Jun 30, 2020 | -32,598.72% |
| Mar 31, 2020 | 725.18% |
| Dec 31, 2019 | 1,834.56% |
| Sep 30, 2019 | -101.01% |
| Jun 30, 2019 | -70.04% |
| Mar 31, 2019 | -185.47% |
| Dec 31, 2018 | -29.98% |
| Sep 30, 2018 | -77.62% |
| Jun 30, 2018 | -100.20% |
| Mar 31, 2018 | -99.17% |
| Dec 31, 2017 | -31.22% |
| Sep 30, 2017 | -29.49% |